Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Next Previous
Trial Profile

A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 18 Apr 2017 Results of population pharmacokinetic analysis using data from 104 pediatric patients diagnosed with relapsed acute lymphoblastic leukaemia (NCT00873093, N = 51) or de novo acute myelogenous leukaemia (NCT01371981, N = 53), published in the Journal of Clinical Pharmacology.
  • 12 Mar 2016 Pooled population pharmacokinetic analysis (n=104) of 2 studies - AAML1031 and AALL07P1 were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 12 Mar 2016 Pooled analysis results on population pharmacokinetic analysis (n=104), from this and the other phase III trial presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top